vs
Strata Critical Medical, Inc.（SRTA）与U S PHYSICAL THERAPY INC（USPH）财务数据对比。点击上方公司名可切换其他公司
U S PHYSICAL THERAPY INC的季度营收约是Strata Critical Medical, Inc.的8.9倍（$202.7M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 12.3%）。U S PHYSICAL THERAPY INC自由现金流更多（$21.0M vs $-10.2M）。过去两年U S PHYSICAL THERAPY INC的营收复合增速更高（14.1% vs -33.6%）
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
该企业是美国领先的门诊康复服务提供商，运营数百间线下物理治疗门诊，为受伤、术后、慢性疼痛及行动障碍人群提供康复护理，同时覆盖运动医学、职业治疗、儿童康复等特色服务领域。
SRTA vs USPH — 直观对比
营收规模更大
USPH
是对方的8.9倍
$22.7M
营收增速更快
SRTA
高出348.9%
12.3%
自由现金流更多
USPH
多$31.2M
$-10.2M
两年增速更快
USPH
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $22.7M | $202.7M |
| 净利润 | — | $4.2M |
| 毛利率 | -0.9% | 19.8% |
| 营业利润率 | -18.4% | 8.3% |
| 净利率 | — | 2.0% |
| 营收同比 | 361.2% | 12.3% |
| 净利润同比 | — | -55.1% |
| 每股收益（稀释后） | $-0.11 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SRTAUSPH
| Q4 25 | $22.7M | $202.7M | ||
| Q3 25 | $49.3M | $197.1M | ||
| Q2 25 | $70.8M | $197.3M | ||
| Q1 25 | $54.3M | $183.8M | ||
| Q4 24 | $-8.7M | $180.4M | ||
| Q3 24 | $36.1M | $168.0M | ||
| Q2 24 | $67.9M | $167.2M | ||
| Q1 24 | $51.5M | $155.7M |
净利润SRTAUSPH
| Q4 25 | — | $4.2M | ||
| Q3 25 | $57.4M | $13.1M | ||
| Q2 25 | $-3.7M | $12.4M | ||
| Q1 25 | $-3.5M | $9.9M | ||
| Q4 24 | — | $9.2M | ||
| Q3 24 | $-2.0M | $6.6M | ||
| Q2 24 | $-11.3M | $7.5M | ||
| Q1 24 | $-4.2M | $8.0M |
毛利率SRTAUSPH
| Q4 25 | -0.9% | 19.8% | ||
| Q3 25 | 23.6% | 18.7% | ||
| Q2 25 | 25.1% | 21.1% | ||
| Q1 25 | 22.1% | 16.9% | ||
| Q4 24 | — | 18.0% | ||
| Q3 24 | 20.8% | 17.3% | ||
| Q2 24 | 24.1% | 20.3% | ||
| Q1 24 | 19.7% | 18.2% |
营业利润率SRTAUSPH
| Q4 25 | -18.4% | 8.3% | ||
| Q3 25 | -11.4% | 12.8% | ||
| Q2 25 | -7.0% | 12.6% | ||
| Q1 25 | -14.0% | 10.7% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | -19.7% | 7.6% | ||
| Q2 24 | -17.9% | 9.3% | ||
| Q1 24 | -19.2% | 9.6% |
净利率SRTAUSPH
| Q4 25 | — | 2.0% | ||
| Q3 25 | 116.5% | 6.7% | ||
| Q2 25 | -5.3% | 6.3% | ||
| Q1 25 | -6.4% | 5.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | -5.4% | 3.9% | ||
| Q2 24 | -16.7% | 4.5% | ||
| Q1 24 | -8.2% | 5.2% |
每股收益（稀释后）SRTAUSPH
| Q4 25 | $-0.11 | $-0.44 | ||
| Q3 25 | $0.70 | $0.48 | ||
| Q2 25 | $-0.05 | $0.58 | ||
| Q1 25 | $-0.04 | $0.80 | ||
| Q4 24 | $-0.11 | $0.52 | ||
| Q3 24 | $-0.03 | $0.39 | ||
| Q2 24 | $-0.15 | $0.47 | ||
| Q1 24 | $-0.06 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.0M | $35.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $279.1M | $476.4M |
| 总资产 | $325.5M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SRTAUSPH
| Q4 25 | $31.0M | $35.6M | ||
| Q3 25 | $22.8M | $31.1M | ||
| Q2 25 | $58.8M | $34.1M | ||
| Q1 25 | $34.8M | $39.2M | ||
| Q4 24 | $18.4M | $41.4M | ||
| Q3 24 | $20.0M | $117.0M | ||
| Q2 24 | $26.3M | $112.9M | ||
| Q1 24 | $36.8M | $132.3M |
股东权益SRTAUSPH
| Q4 25 | $279.1M | $476.4M | ||
| Q3 25 | $283.0M | $503.6M | ||
| Q2 25 | $223.1M | $500.8M | ||
| Q1 25 | $219.7M | $497.3M | ||
| Q4 24 | $221.9M | $488.9M | ||
| Q3 24 | $233.5M | $482.8M | ||
| Q2 24 | $229.4M | $484.6M | ||
| Q1 24 | $236.6M | $479.8M |
总资产SRTAUSPH
| Q4 25 | $325.5M | $1.2B | ||
| Q3 25 | $335.1M | $1.2B | ||
| Q2 25 | $257.9M | $1.2B | ||
| Q1 25 | $250.6M | $1.2B | ||
| Q4 24 | $256.7M | $1.2B | ||
| Q3 24 | $282.9M | $1.0B | ||
| Q2 24 | $280.3M | $1.0B | ||
| Q1 24 | $282.8M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.3M | $24.9M |
| 自由现金流经营现金流 - 资本支出 | $-10.2M | $21.0M |
| 自由现金流率自由现金流/营收 | -44.7% | 10.4% |
| 资本支出强度资本支出/营收 | 8.1% | 1.9% |
| 现金转化率经营现金流/净利润 | — | 6.00× |
| 过去12个月自由现金流最近4个季度 | $-58.5M | $61.0M |
8季度趋势，按日历期对齐
经营现金流SRTAUSPH
| Q4 25 | $-8.3M | $24.9M | ||
| Q3 25 | $-37.3M | $19.9M | ||
| Q2 25 | $-3.1M | $34.9M | ||
| Q1 25 | $-246.0K | $-4.7M | ||
| Q4 24 | $-1.8M | $19.4M | ||
| Q3 24 | $6.4M | $22.1M | ||
| Q2 24 | $8.4M | $29.0M | ||
| Q1 24 | $-15.6M | $4.4M |
自由现金流SRTAUSPH
| Q4 25 | $-10.2M | $21.0M | ||
| Q3 25 | $-40.1M | $15.6M | ||
| Q2 25 | $-5.4M | $31.6M | ||
| Q1 25 | $-2.9M | $-7.3M | ||
| Q4 24 | $-6.3M | $16.9M | ||
| Q3 24 | $-3.0M | $19.6M | ||
| Q2 24 | $-7.7M | $26.7M | ||
| Q1 24 | $-16.4M | $2.6M |
自由现金流率SRTAUSPH
| Q4 25 | -44.7% | 10.4% | ||
| Q3 25 | -81.4% | 7.9% | ||
| Q2 25 | -7.6% | 16.0% | ||
| Q1 25 | -5.3% | -3.9% | ||
| Q4 24 | 72.7% | 9.4% | ||
| Q3 24 | -8.2% | 11.7% | ||
| Q2 24 | -11.4% | 15.9% | ||
| Q1 24 | -31.8% | 1.7% |
资本支出强度SRTAUSPH
| Q4 25 | 8.1% | 1.9% | ||
| Q3 25 | 5.7% | 2.2% | ||
| Q2 25 | 3.2% | 1.6% | ||
| Q1 25 | 4.8% | 1.4% | ||
| Q4 24 | -52.6% | 1.4% | ||
| Q3 24 | 25.8% | 1.5% | ||
| Q2 24 | 23.8% | 1.4% | ||
| Q1 24 | 1.6% | 1.2% |
现金转化率SRTAUSPH
| Q4 25 | — | 6.00× | ||
| Q3 25 | -0.65× | 1.52× | ||
| Q2 25 | — | 2.81× | ||
| Q1 25 | — | -0.47× | ||
| Q4 24 | — | 2.10× | ||
| Q3 24 | — | 3.34× | ||
| Q2 24 | — | 3.86× | ||
| Q1 24 | — | 0.55× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
USPH
| Net Patient Revenues | $169.7M | 84% |
| Industrial Injury Prevention Services Revenues | $28.9M | 14% |
| Management Contract Revenues | $2.3M | 1% |
